Jounce shares take a beating as their lead drug spurs only a weak response in PhII — trial halted
A little over two months after Jounce Therapeutics $JNCE sold its latest experimental cancer drug to Gilead, the company’s lead program has failed to clear the Phase II hurdle.
Jounce’s Phase II study evaluating the ICOS-targeting vopratelimab in non-small cell lung cancer flopped with only 1 of 50 patients showing an overall response, and the company has decided to shut the trial down rather than continue enrollment, the biotech announced Monday. Researchers had been studying whether or not vopratelimab could produce a meaningful response in combination with BMS’ Yervoy for patients with PD-(L)1 resistant NSCLC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.